Literature DB >> 28330695

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

Masataka Suzuki1.   

Abstract

Mesh:

Year:  2017        PMID: 28330695      PMCID: PMC5383639          DOI: 10.1016/j.ymthe.2017.03.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  13 in total

Review 1.  Adoptive cell transfer as personalized immunotherapy for human cancer.

Authors:  Steven A Rosenberg; Nicholas P Restifo
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

2.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

3.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

5.  Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Authors:  Diana M Rommelfanger; Phonphimon Wongthida; Rosa M Diaz; Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Richard G Vile
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

6.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

Authors:  Igor Puzanov; Mohammed M Milhem; David Minor; Omid Hamid; Ai Li; Lisa Chen; Michael Chastain; Kevin S Gorski; Abraham Anderson; Jeffrey Chou; Howard L Kaufman; Robert H I Andtbacka
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

7.  Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Authors:  Julia V Cockle; Karishma Rajani; Shane Zaidi; Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Kevin Shim; Tim Peterson; Ian F Parney; Susan Short; Peter Selby; Elizabeth Ilett; Alan Melcher; Richard Vile
Journal:  Neuro Oncol       Date:  2015-09-26       Impact factor: 12.300

8.  A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells.

Authors:  Meromit Singer; Chao Wang; Le Cong; Nemanja D Marjanovic; Monika S Kowalczyk; Huiyuan Zhang; Jackson Nyman; Kaori Sakuishi; Sema Kurtulus; David Gennert; Junrong Xia; John Y H Kwon; James Nevin; Rebecca H Herbst; Itai Yanai; Orit Rozenblatt-Rosen; Vijay K Kuchroo; Aviv Regev; Ana C Anderson
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

Review 9.  Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.

Authors:  Padma Sampath; Steve H Thorne
Journal:  Oncolytic Virother       Date:  2015-06-18

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  2 in total

1.  Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells.

Authors:  Andrew T Crane; Matthew R Chrostek; Venkatramana D Krishna; Maple Shiao; Nikolas G Toman; Clairice M Pearce; Sarah K Tran; Christopher J Sipe; Winston Guo; Joseph P Voth; Shivanshi Vaid; Hui Xie; Wei-Cheng Lu; Will Swanson; Andrew W Grande; Mark R Schleiss; Craig J Bierle; Maxim C-J Cheeran; Walter C Low
Journal:  PLoS One       Date:  2020-10-01       Impact factor: 3.240

Review 2.  Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?

Authors:  Yuguo Zhang; Bolni Marius Nagalo
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.